Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.
Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one da...
Main Authors: | Pierre Bessière, Marine Wasniewski, Evelyne Picard-Meyer, Alexandre Servat, Thomas Figueroa, Charlotte Foret-Lucas, Amelia Coggon, Sandrine Lesellier, Frank Boué, Nathan Cebron, Blandine Gausserès, Catherine Trumel, Gilles Foucras, Francisco J Salguero, Elodie Monchatre-Leroy, Romain Volmer |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-08-01
|
Series: | PLoS Pathogens |
Online Access: | https://doi.org/10.1371/journal.ppat.1009427 |
Similar Items
-
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
by: Charlotte Primard, et al.
Published: (2023-06-01) -
Th17-related mammary immunity, but not a high systemic Th1 immune response is associated with protection against E. coli mastitis
by: Nathan Cebron, et al.
Published: (2020-11-01) -
Assessment of BoHV-4-based vector vaccine intranasally administered in a hamster challenge model of lung disease
by: Seok-Chan Park, et al.
Published: (2023-07-01) -
EPAC1 Pharmacological Inhibition with AM-001 Prevents SARS-CoV-2 and Influenza A Virus Replication in Cells
by: Charlotte Foret-Lucas, et al.
Published: (2023-01-01) -
Establishment of a Nipah Virus Disease Model in Hamsters, including a Comparison of Intranasal and Intraperitoneal Routes of Challenge
by: Stephen Findlay-Wilson, et al.
Published: (2023-07-01)